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VarScan 2: Somatic mutation and copy number
alteration discovery in cancer by exome sequencing
Daniel C. Koboldt,1 Qunyuan Zhang,1 David E. Larson,1 Dong Shen,1
Michael D. McLellan,1 Ling Lin,1 Christopher A. Miller,1 Elaine R. Mardis,1,2,3 Li Ding,1,2,4
and Richard K. Wilson1,2,3,4
1

The Genome Institute, Washington University, St. Louis, Missouri 63108, USA; 2Department of Genetics, Washington University,
St. Louis, Missouri 63110, USA; 3Siteman Cancer Center, Washington University, St. Louis, Missouri 63110, USA
Cancer is a disease driven by genetic variation and mutation. Exome sequencing can be utilized for discovering these
variants and mutations across hundreds of tumors. Here we present an analysis tool, VarScan 2, for the detection of
somatic mutations and copy number alterations (CNAs) in exome data from tumor–normal pairs. Unlike most current
approaches, our algorithm reads data from both samples simultaneously; a heuristic and statistical algorithm detects
sequence variants and classifies them by somatic status (germline, somatic, or LOH); while a comparison of normalized
read depth delineates relative copy number changes. We apply these methods to the analysis of exome sequence data from
151 high-grade ovarian tumors characterized as part of the Cancer Genome Atlas (TCGA). We validated some 7790
somatic coding mutations, achieving 93% sensitivity and 85% precision for single nucleotide variant (SNV) detection.
Exome-based CNA analysis identified 29 large-scale alterations and 619 focal events per tumor on average. As in our
previous analysis of these data, we observed frequent amplification of oncogenes (e.g., CCNE1, MYC) and deletion of tumor
suppressors (NF1, PTEN, and CDKN2A). We searched for additional recurrent focal CNAs using the correlation matrix
diagonal segmentation (CMDS) algorithm, which identified 424 significant events affecting 582 genes. Taken together, our
results demonstrate the robust performance of VarScan 2 for somatic mutation and CNA detection and shed new light on
the landscape of genetic alterations in ovarian cancer.
[Supplemental material is available for this article.]
Exome sequencing of tumor samples and matched normal controls has the potential to rapidly identify protein-altering mutations across hundreds of patients, potentially enabling the discovery of recurrent events driving tumor development and growth
(International Cancer Genome Consortium 2010; Stratton 2011).
Yet the analysis of such data presents significant challenges. Sequencing coverage is nonuniform across targeted regions and
from one sample to the next (Ng et al. 2009; Bainbridge et al.
2010; Teer et al. 2010). Many regions achieve high read depth
(more than 1003), which can confound variant callers and depthbased filters if not properly addressed (Ku et al. 2011). Repetitive
and paralogous sequences can give rise to numerous false positives.
The detection of somatic mutations in tumor genomes is even
more challenging. The genomes of primary tumors are genetically heterogeneous (Ding et al. 2010), with frequent rearrangements (Campbell et al. 2008) and copy number alterations (CNAs)
(Beroukhim et al. 2010). Further, somatic mutations are relatively
rare compared with germline variation, often representing <0.1%
of variants in a tumor genome (Ley et al. 2008; Mardis et al. 2009).
Simply subtracting variants in the matched normal from variants
in the tumor (Wei et al. 2011) is poorly suited for the analysis of
exome sequence data, because it fails to account for regions that
were undersampled in the normal. Accurate mutation detection
requires a direct, simultaneous comparison of tumor–normal pairs
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at every position in the exome, but few algorithms to do so have
been described.
Numerous algorithms have been developed to assess genomewide copy number using whole-genome sequencing (WGS) data.
Most of these approaches (Campbell et al. 2008; Alkan et al. 2009;
Chiang et al. 2009; Yoon et al. 2009; Abyzov et al. 2011) would
be confounded by exome data sets, because of the biases introduced
by hybridization and the sparse and uneven coverages throughout
the genome. However, when both DNA samples in a tumor–normal
pair were captured and sequenced under identical hybridization
conditions, we reasoned that it might be possible to detect somatic
CNAs (SCNAs) as deviations from the log-ratio of sequence coverage
depth within a tumor–normal pair, and then quantify the deviations statistically. Such an approach would provide a gene-centric
view of copy number in a tumor sample, though it would be limited
to the ;1% of the genome captured by current exome platforms.
Previously, we published VarScan (Koboldt et al. 2009), an
algorithm for variant detection in next-generation sequencing
data. We have since released a new tool, VarScan 2 (http://varscan.
sourceforge.net), with several improvements, including the ability
to identify somatic mutation, loss of heterozygosity (LOH), and
CNA events in tumor–normal pairs. VarScan 2 analyzes sequence
data from a tumor sample and its corresponding normal sample
simultaneously, applying heuristic methods and a statistical test to
detect variants—single nucleotide variants (SNVs) and insertions/
deletions (indels)—and classify them by somatic status. By direct
comparison of normalized sequence depth, our method also detects
SCNAs in the tumor genome.
Here, we utilize VarScan 2 for the analysis of exome sequence
data from 151 patients with high-grade serous ovarian adenocar-
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cinoma (HGS-OVCa) that were initially characterized within the
Cancer Genome Atlas (TCGA) project (Cancer Genome Atlas Research Network 2011). We present a robust pipeline for the detection of both germline (inherited) and somatic (acquired) mutations by exome sequencing and describe filtering approaches for
detecting variants with high sensitivity and specificity. To evaluate
the performance of our SCNA detection algorithm, we compare
our results to copy number data from high-density SNP array
and WGS approaches. Our results demonstrate the accuracy of
VarScan 2 for somatic mutation and CNA detection and enable a
new survey of the genetic landscape in ovarian carcinoma.

Results
The VarScan 2 algorithm reads SAMtools pileup or mpileup output
from tumor and normal samples simultaneously, performing
pairwise comparisons of base calls and normalized sequence depth
at each position (Fig. 1). For variant detection, a heuristic algorithm determines the genotype for normal and tumor samples
independently based on adjustable minimum thresholds for coverage, base quality, variant allele frequency, and statistical significance. In single samples, the latter value is computed by Fisher’s
exact test of the read counts supporting each allele (reference and
variant) compared to the expected distribution based on sequencing error alone. By default, VarScan 2 requires a minimum coverage
of 33, minimum phred base quality of 20, allele frequency of at
least 8%, and a P-value of <0.05. Variants with a variant allele
frequency of >75% are called homozygous. These represent the
initially recommended parameters, and they are fully adjustable by
the user.

Figure 1. The VarScan 2 mutation and copy number alteration detection algorithms. Alignments in BAM format for a tumor–normal pair
are read simultaneously to identify inherited (germline), loss-of-heterozygosity (LOH), and somatic mutation events. Variants in each category
are further classified as high confidence (HC) or low confidence (LC). HC
variants are filtered to remove false positives from common sequencingand alignment-related artifacts (see Table 1). The resulting variants are
annotated and organized by tier; the average number of ‘‘tier 1’’ coding
variants per tumor is shown for each category. At positions with at least
203 coverage (default), copy number alterations are detected by comparison of Q20 read depths from matched tumor–normal pairs, normalized based on the amount of input data for each sample. Raw contiguous
regions from VarScan 2 are processed by circular binary segmentation
(CBS) and a subsequent merging procedure that joins adjacent segments
yields a set of somatic copy number alterations, which are further classified
as large-scale (>25% of chromosome arm) or focal (<25%) events. Shown
are the average numbers of events detected in 142 ovarian exomes.

At every position where one or both samples had a variant,
VarScan performs a direct comparison between tumor and normal
genotypes (heuristic) and supporting read counts (Fisher’s exact
test) to determine the somatic status. Variants present in both
samples are classified as somatic (acquired), variants heterozygous
in the normal but homozygous in the tumor are classified as LOH,
and variants shared between samples are classified as germline
(inherited). To further refine these predictions, we developed
a false-positive filter that removes likely false positives due to sequencing- or alignment-related artifacts. The filter evaluates each
variant for nine empirically derived criteria to distinguish true
variants from probable artifactual calls (Table 1; Supplemental
Fig. 1).
To identify SCNAs, VarScan 2 compares Q20 (base quality $
20) read depths between tumor and normal samples for contiguous
regions of coverage. After normalizing for the amount of input
data (unique bases mapped), the relative copy number change is
inferred as the log2 of the ratio of tumor depth to normal depth for
each contiguous region. The output of this algorithm—a set of
regions, each with defined start and stop positions and a log ratio
representing the copy number change in the tumor—is similar to
hybridization-based copy number data and amenable to the same
segmentation methods. Therefore, we apply a circular binary segmentation (CBS) algorithm (Seshan and Olshen 2010) to delineate
segments by copy number and identify significant change-points.
A subsequent joining procedure merged adjacent segments of
similar copy number and classified them as either large-scale
(>25% of chromosome arm) or focal events (see Methods).

Application to 151 ovarian cancer tumor–normal pairs
To evaluate our methods, we applied them to exome data for tumor
samples and matched normals from 151 serous ovarian carcinomas that we previously characterized (Cancer Genome Atlas Research Network 2011) as part of the Cancer Genome Atlas (Table 2).
On average, we identified 18,462 coding SNVs per tumor, of which
16,340 (88.5%) were germline variants, 2013 (10.9%) were LOH
events, and 109 (0.59%) were somatic mutations (Fig. 1). Gapped
alignments of the relatively long (76–100 bp), paired-end reads
in our data set also permitted the identification of small indels
ranging in size from 1–55 bp. On average, we detected 418 coding
indels per exome, of which 387 (92.6%) were germline variants, 23
(5.50%) were LOH, and eight (1.91%) were somatic mutations.
We also applied VarScan 2 to detect SCNAs. To minimize the
effect of variable coverage between tumor and normal samples, we
excluded nine samples with <50% of target CDS bases covered at
greater than 20-fold, and focused our analysis on 142 tumor–
normal pairs with sufficient sequence coverage (Supplemental
Information; Supplemental Table 1). On average across 142 patient
samples, we detected 29 large-scale events (eight gains and 21
losses) and 619 focal events (301 gains and 318 losses) per tumor
exome (Fig. 1; Supplemental Table 5).

Comparison of germline variants to high-density SNP
array genotypes
To evaluate the performance of our mutation detection approach,
we utilized orthogonal validation data from two sources. First, to
evaluate the accuracy of germline variant detection, we compared
VarScan 2 consensus genotypes for exome data to high-density
SNP array data made available by TCGA (Cancer Genome Atlas
Research Network 2011). To minimize the influence of sequence
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Table 1.

Empirically derived filtering parameters for putative somatic mutations

Parameter
Read position
Strandedness
Variant reads
Variant frequency
Distance to 39
Homopolymer
Map quality difference
Read length difference
MMQS difference

Description

Requirement

Average variant position in supporting reads,
relative to read length
Fraction of supporting reads from the forward
strand
Total number of reads supporting the variant
Variant allele frequency inferred from read
counts
Average distance to effective 39 end of variant
position in supporting reads
Number of bases in a flanking homopolymer
matching one allele
Difference in average mapping quality
between reference and variant reads
Difference in average trimmed read length
between reference and variant reads
Difference in average mismatch quality sum
between variant and reference reads

Between 10 and 90

coverage, we compared only sites that achieved eightfold coverage
or higher in either the tumor or matched normal sample, and examined only those within the ;33-Mbp CDS target region. On
average, each sample had 5425 germline SNPs with informative
array genotypes and sufficient coverage in the exome. Genotype
concordance between VarScan 2 consensus genotypes and array
genotypes was 99.56% (Supplemental Information; Supplemental
Fig. 2A), supporting a high accuracy for germline variant detection
by VarScan 2.
To better understand concordance metrics, we investigated
the 2854 discrepancies between array and exome data (Supplemental Fig. 2B). Of these, 27% of these were genotyped as reference
(wild type) by array but called heterozygous (21%) or homozygous
variant (6%) in the sequencing data. On average, these sites
achieved high depth (2063 and 1293, respectively) and variant
allele frequencies (46.7% and 97.0%) by exome sequencing (Supplemental Fig. 3). This suggests that many are true variants missed
by the array, possibly due to misclustering or allele dropout
(Koboldt et al. 2006). Another 17% of discrepancies were heterozygous on both platforms, but the variant allele observed in sequence data was different from that reported by SNP array. An
examination of these revealed that the majority (83.3%) were reverse-complementary allele combinations (e.g., G/A variant in
exome data genotyped as C/T); most likely, the strand orientation
reported for the SNP array genotype was incorrect. The most
common discrepancy (45%) occurred at sites called heterozygous
by array but homozygous variant using exome data. Some 105 of
these (8.2%) had 100% variant allele frequency with 203 or more
coverage and are likely true homozygotes, but roughly half of all
such discrepancies (615, or 48%) had less than 203 coverage in
exome data and likely reflect an allelic bias favoring the variant. We
conclude that germline variants called using exome data are highly
accurate (99.56%), and a significant fraction of the discrepancies
can be attributed to array genotyping error or imbalanced allelic
representation in the sequence data.
Finally, to investigate the portion of the exome that is callable
by our method, we computed the fraction of CDS bases covered by
at least 20 reads (Supplemental Table 1) in each sample. As an estimate of overall sensitivity for coding variants, we also determined
the proportion of heterozygous SNPs (by array genotype) in the
CDS target that were detected by VarScan 2 as germline variants,
regardless of the coverage of those positions (Supplemental Fig. 4).
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Between 1%–99%
At least four
At least 5%
At least 20
Less than five

There were nine outlier samples that
achieved relatively poor CDS coverage
with correspondingly poor detection of
heterozygous SNPs. Excluding these, we
find that, on average, 79.62% of CDS
bases are covered 203 or more in each
sample and that 81.42% of heterozygous
SNPs are detected by VarScan 2. From
these metrics, we conclude that ;80%
of coding sequences are ‘‘callable’’ by
Agilent SureSelect exome sequencing and
VarScan 2 analysis.

Less than 30
Less than 25

Orthogonal validation
of somatic mutations

Less than 100

To assess the specificity of somatic mutation detection, we validated putative somatic coding SNVs by PCR and deep
resequencing (Table 3). Of 5871 mutations for which we obtained validation data, 5225 (89.00%) were
confirmed as true somatic mutations, 572 (9.74%) were refuted as
wild type, 63 (1.07%) were germline variants, and 11 (0.19%) were
due to LOH in the tumor. In general, exome sequence depth was
lower and observed variant allele frequency markedly reduced
among predicted SNVs that were refuted as wild type, compared
with validated somatic mutations (Supplemental Fig. 5). We also
attempted to validate 2458 putative mutations that were removed
by the false-positive filter. Of these, 292 were confirmed as valid
somatic mutations (11.88%) while 2073 (84.34%) were refuted as
wild type. Thus, our filtering strategy retained 94.71% of valid
mutations while removing 78.37% of false positives. We conclude
that this approach dramatically increases the true-positive rate of
mutation detection, with a relatively small reduction (5.3%) in
overall sensitivity.
To further assess the sensitivity of mutation detection, we
compared our predictions to validated somatic mutations reported
for 60 tumor–normal pairs that were analyzed externally (Cancer
Genome Atlas Research Network 2011). These cases harbored
a total of 3065 valid somatic mutations, of which we detected 2565
(83.7%). When we investigated the 500 valid mutations missed by
our approach, we found that 93 had been detected but deemed low
confidence (LC), 51 were high confidence (HC) but removed by
the filter, and 298 had less than fourfold coverage in one or both

Table 2.

Exome sequencing data set summary

Exome platform
Genes targeted
Exons targeted
CDS target size
Sequencing platform
Number of patients
Number of samples
Read length
Sequence per sample
Average mapping rate
Average duplication rate

WU

BI

SureSelect (Agilent)
18,568
188,260
33 Mbp
Illumina GAIIx
91
182
2 3 100 bp
15.2 Gbp
98.34%
12.58%

SureSelect (Agilent)
18,568
188,260
33 Mbp
Illumina GAIIx
60
120
2 3 76 bp
21.9 Gbp
81.06%
18.50%

There were 91 tumor–normal pairs sequenced at Washington University
(WU); BAM files for an additional 60 tumor–normal pairs sequenced at the
Broad Institute of MIT and Harvard (BI) were downloaded from dbGaP.
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Table 3. Estimated sensitivity and precision of mutation
detection with VarScan 2 based upon orthogonal validation data
Experimental validation (91 cases)
Total with validation data
Validated somatic
Validated germline
Validated loss of heterozygosity
Validated wild type
Sensitivity for valid somatic mutations
Precision of mutation calls

5871
5225
63
11
572
92.30%
89.00%

Detection of reported mutations (60 external cases)
Valid somatic mutations reported
Valid somatic mutations with coverage
Detected by VarScan
Detection sensitivity
Adjusted sensitivity

3065
2773
2565
83.69%
92.50%

Sensitivity refers to the fraction of known, validated somatic mutations
that were detected, whereas precision reflects the proportion of detected
SNVs that were validated. In externally analyzed samples, we also compute the ‘‘adjusted sensitivity,’’ which reflects the detection of known,
validated somatic mutations with sufficient coverage in the BAM files
analyzed.

samples at the time the binary alignment/map (BAM) files were
downloaded (Supplemental Information; Supplemental Table 2).
By adjusting for uncovered sites, our approach identified 2565 of
2767 (92.70%) mutations with sufficient sequence coverage. Taken
together, these results demonstrate that our approach yields high
sensitivity and precision for somatic mutation detection.
We attempted to validate 141 HC somatic indels detected by
VarScan 2. Of these, 85 (60.28%) were confirmed as somatic, 30
(21.28%) were refuted as wild type, and 26 (18.4%) were found to
be germline or LOH events (Supplemental Table 8). There were also
80 validated somatic indels among the externally analyzed tumor–
normal pairs. Some 73 had coverage in the BAM files that we
downloaded; of these, 65 (89.04%) were detected as HC somatic
mutations by VarScan 2. While more comprehensive evaluations
are needed, these results suggest that our method detects somatic
indels with high sensitivity (89%) but a moderate true-positive rate
(60%).

Comparison to single-sample methods for somatic
mutation detection
We next sought to demonstrate the superiority of our method,
which compares tumor and normal samples simultaneously, to
more simplistic approaches for somatic mutation calling. For this
analysis, we selected five ovarian cancer cases for which both
exome and whole-genome sequencing (WGS) data were available
(marked in Supplemental Table 1). By using the exome data, we
identified tumor-specific SNPs by a simple subtraction method (see
Supplemental Methods), which yielded 152,708 candidate mutations per tumor (on average). In contrast, VarScan 2 detected 508
somatic mutations per tumor (on average) for the same data set
(Supplemental Table 9).
Given the large number of calls generated by the subtraction
method, it was possible that a significant fraction of these were
valid somatic mutations that had not been part of our validation
experiment. To investigate this possibility, we determined the
fraction of mutations called in each set that were also detected in
the WGS data by a different algorithm, named SomaticSniper
(Larson et al. 2011). Of the 2538 HC mutations called by VarScan

in exome data, 1716 (67.61%) were called by SomaticSniper in
WGS data. In contrast, only 7353 of 763,539 calls (0.96%) made by
the subtraction method were supported by SomaticSniper calls.
Next, we evaluated the sensitivity of each method to detect
the known somatic mutations described above. A total of 290
validated somatic mutations had been reported for these five cases
in the TCGA study. Of these, 247 (85.17%) were found by the
subtraction method, while 264 (91.03%) were detected by VarScan
2 (Supplemental Table 9). Surprisingly, these results suggest that
a subtraction method may also suffer slightly lower sensitivity
for valid somatic mutations, possibly due to false-positive calls in
the matched normal sample. We conclude that our method for
somatic mutation calling delivers comparable sensitivity and
dramatically higher precision, than do simple subtraction-based
approaches.

Orthogonal validation of SCNAs
To evaluate the accuracy of SCNA detection, we compared copy
number data for five ovarian tumors that were assessed by highdensity SNP array, exome, and WGS (see Supplemental Methods).
Strikingly, the exome-based copy number estimates from our algorithm were remarkably consistent with those of array and WGS
data and demonstrated an ability to detect both large-scale and
focal events (see example in Fig. 2A). A systematic comparison of
these three approaches is more difficult, since both array and
exome data are limited to a very small fraction of the genome (SNPs
and exons, respectively); only WGS yields unbiased genome-wide
copy number estimates. All three approaches, however, should be
able to detect large-scale gains and losses of chromosome arms
because these events typically span several megabases. Thus, we
compared the overlap of large-scale events from exome, array, and
WGS data sets for the five cases (Fig. 2B; Supplemental Table 3). A
total of 206 large-scale CNAs were detected, of which 165 (80.10%)
were detected by all three approaches, suggesting that most of
these represent real events. Our exome-based method predicted
185 large-scale events (90% of the total); nearly all were supported
by array or WGS data sets, and 89.2% were supported by both. A
visual review of events not detected by WGS or array revealed that
most were present but did not meet thresholds for calling an amplification (log2 ratio > 0.20) or deletion (log2 ratio < 0.10). In
contrast, the ;10% of large-scale events missed by our exome
method were largely due to oversegmentation in sparsely targeted
regions of the genome. WGS data sets yielded the most calls
overall, likely reflecting a wider and more unbiased coverage of the
genome.
A similar comparison for focal copy number events is challenging, since exome and SNP array data sets survey different,
noncontiguous portions of the genome. To address this, we performed a three-platform comparison of copy number events affecting coding sequences. At every exon, we determined a copy
number status (amplification, deletion, or neutral) based upon the
best-overlapping segment from SNP array, exome, or WGS copy
number data sets. There were 677,434 copy-number–altered exons
(about 135,000 per case) in the five cases at which we could make
this comparison. Of these, 72.1% were detected by two platforms
and 44.49% were detected by all three (Fig. 2C), suggesting that
this comparison strategy is reasonably accurate given the different
portions of the genome surveyed by each platform.
Our exome-based method detected 488,721 focal events
(72.14% of the total), achieving higher sensitivity than the SNP
array (65.39%) but lower than WGS (79.05%). This result is
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Figure 2. Detection of large-scale and focal copy number alterations by sequencing- and array-based approaches. (A) Deletions and focal amplifications
of chromosome 4 in sample TCGA-24-1103. Copy number estimates from array (gray), WGS (light blue), and exome (dark blue) indicate two regions of
deletion as well as a focal amplification (window). Red lines indicate segmented exome CBS calls. (Below) Variant allele frequencies in the normal (blue) and
tumor (green) indicate regions of loss of heterozygosity (LOH) in deleted segments. (B) Intersection of large-scale copy number alterations detected by
SNP array, whole-genome sequencing, and exome sequencing approaches for five HGS-OVCa cases. For details, see Supplemental Table 3. (C ) Intersection of gene-level (focal) copy number alterations detected by SNP array, whole-genome sequencing, and exome sequencing approaches for five
HGS-OVCa cases.

somewhat unsurprising, given the limited resolution of SNP arrays
and the superior coverage breadth and uniformity offered by WGS.
If we consider the intersection of events supported by both the
array and WGS platforms to be a gold standard, there were 395, 868
such focal events, of which our method detected 301,376
(76.13%). There were 161,944 events (23.91%) detected by exome
or WGS methods but not by SNP arrays, consistent with the expectation of limited resolution for the array platform. A significant
portion of the focal events that we detected using exome data
(80.60%) were supported by at least one other platform, suggesting
that the majority are likely to be real events. This is particularly
promising because the exome method detected a higher fraction of
platform-specific calls (94,819), which are likely to include small
focal copy number changes missed by other platforms.
Encouraged by these results, we next compared recurrent
large-scale gains and losses in the 142 exome cases included in this
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study to those of a larger data set (489 cases, array data) analyzed by
TCGA (Cancer Genome Atlas Research Network 2011). Most of the
cases we studied were part of the TCGA analysis, which identified
30 recurrent large-scale alterations (eight gains and 22 losses), all of
which had been reported previously. Our method identified all
recurrent gains and losses reported by TCGA (Fig. 3; Supplemental
Information; Supplemental Table 4; Cancer Genome Atlas Research Network 2011). Further, the frequencies of arm-level events
detected in our data set and the TCGA data set were highly correlated (r 2 = 0.84 for gains, 0.86 for losses), suggesting that our
exome-based approach was sufficiently robust to recapitulate the
results of our previous array-based findings. Taken together, the
results suggest that our method identifies somatic CNAs with an
accuracy comparable to array-based and WGS approaches and that
our set of 142 cases is representative of the larger cohort (n = 489)
studied by TCGA.
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ularly sensitive for focal events. Our analysis identified 424
significant focal RCNAs targeting 582 known genes (Supplemental
Table 6). Gene set analysis of these 582 genes revealed 10 significantly enriched pathways (P < 0.0005) (Supplemental Table 7).
Focal adhesion (23 genes, P = 1.22 3 1013) and ECM–receptor
interaction (15 genes, P = 7.87 3 1012) were the most significant
pathways, suggesting that cell–cell and cell–matrix adhesion
molecules are often dysregulated in high-grade ovarian carcinoma.

Discussion

Figure 3. Recurrent chromosome-arm gains and losses in ovarian
cancer. Eight significant gains and 22 significant losses of chromosome
arms identified by TCGA in SNP array data for 489 cases were recapitulated using exome data for 142 cases. Observed frequencies were
highly correlated between data sets for both gains (r 2 = 0.84) and
losses (r 2 = 0.86).

Identification of recurrent CNAs with CMDS

In summary, we have developed an approach for simultaneous
detection of germline variants, somatic mutations, LOH, and
SCNAs using exome sequence data from matched tumor and
normal samples. Unlike other methods for mutation detection, our
algorithm reads data from tumor and normal samples simultaneously, enabling direct pairwise comparisons of base calls at each
position. For germline variant detection, we observed a high genotype concordance (99.56%) between the VarScan results and
high-density SNP arrays, with a significant fraction of discordant
sites attributed to imbalanced allelic representation or errors in the
array data.
For somatic mutation detection, we demonstrated that our
method provides similar sensitivity and a dramatically higher truepositive rate compared with more simplistic approaches that analyze tumor and normal samples independently. We also demonstrated that our filtering strategy removes the vast majority of false
positives due to sequencing or alignment artifacts, while preserving sensitivity for true mutations. Indeed, in exome sequence
data for 151 ovarian tumors characterized by TCGA, our approach
identified 5225 valid somatic mutations with 94.71% sensitivity
and a 89.00% true-positive rate. We observed a comparable sensitivity (89%) and a moderate true-positive rate (60%) for validated
somatic indels, though the number of such variants in our data set

High-grade serous ovarian tumors possess highly rearranged genomes, owing in part to defects in homologous recombination
pathways (Patel et al. 1998; Xu et al. 1999; Bowtell 2010; Cancer
Genome Atlas Research Network 2011). Genetic alterations that
promote carcinogenesis, e.g., the amplification of oncogenes and
deletion of tumor-suppressor genes, are likely to be recurrent across
multiple tumors. Indeed, when we analyzed the mean copy
number change across 142 cases genome-wide (Fig. 4), we observed
a striking pattern of recurrent copy number events. Many of these
correspond to large-scale gains and losses
shown in Figure 3. Focal amplifications
and deletions are also apparent; the majority of these have already been reported
in ovarian cancer (Cancer Genome Atlas
Research Network 2011). Notable examples include amplifications MYC, CCNE1,
and EVI1 (also called MECOM), as well
as deletions of tumor suppressors NF1,
PTEN, and CDKN2A/CDKN2B (Fig. 5).
Intriguingly, we also observed tight
focal amplifications of EPH receptors
EPHB3 (3q27) and EPHB4 (7q22) (Figs. 4,
5), which are known to be overexpressed
in ovarian carcinoma (Alam et al. 2008)
but were not significant in SNP array data
for 489 cases analyzed by TCGA. We reasoned that the high-resolution, exomecentric nature of our data set might enable identification of new recurrent CNAs
(RCNAs) in ovarian cancer. To identify
such regions, we applied the correlation
matrix diagonal segmentation (CMDS)
algorithm (Zhang et al. 2010) to segmented exome-based copy number data
Figure 4. Global copy number alteration profile of ovarian cancer. Average log of copy number
for 142 cases. CMDS employs a pop- difference is plotted for chromosomes 1–22 and X. Amplifications are shown in red,2deletions in blue,
ulation-based approach to identify sta- and neutral regions in gray. Significant peaks associated with known oncogenes or tumor suppressor
tistically significant RCNAs and is partic- genes are indicated.
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Figure 5. Frequent copy number alteration of ovarian cancer genes.
Exome-based copy number estimates were used to compute the proportion of ovarian cancer tumors (n = 142) exhibiting amplification or
deletion of key ovarian cancer genes. Asterisks (*) indicate significantly
altered genes identified from SNP array data in our previous study.

(158) was relatively small. It should also be noted that our method
detects indels based upon gapped Smith-Waterman alignments
and will miss larger events that cannot be spanned by a single
read.
By evaluating tumor and normal samples simultaneously
using heuristics and a Fisher’s exact test, the VarScan 2 algorithm
offers some key advantages for mutation detection in cancer. First,
it exploits the digital nature of massively parallel sequence data to
detect small but significant differences between normal and tumor
samples. This capability is especially important for studies of human cancers, as tumor samples are often genetically heterogeneous (Ding et al. 2010), while matched normals may contain
DNA from malignant cells, particularly among patients with liquid
tumors (Ley et al. 2008; Mardis et al. 2009).
We also described a novel method for detecting SCNAs using
exome data and undertook a number of analyses to demonstrate its
accuracy. First, in five ovarian cancer cases, we compared the results of our method to those of both SNP array and WGS platforms.
These comparisons demonstrated that 95% of large-scale events
and 80% of focal events identified by our approach are supported
by an orthogonal platform. For focal CNAs of coding sequences,
the sensitivity of our method (72%) was higher than that of SNP
arrays (65%) but lower than that of WGS (79%). Second, we
compared RCNAs in our data set of 142 cases to the results of our
previous study (Cancer Genome Atlas Research Network 2011). We
identified all recurrent large-scale CNAs initially reported for these
samples (using array data for 489 cases), with frequencies that were
highly correlated (r2 = 0.84 for gains, 0.86 for losses). We also
confirmed frequent focal copy number perturbations of known
ovarian cancer genes (e.g., gains of MYC, RAB25, and CCNE1 and
losses of NF1, CDKN2A/B, and PTEN) consistent with both our
previous findings and results reported by other studies using different methods (Bast et al. 2009). Further, we identified new putative focal amplifications (EPHB3 and EPHB4) that had not been
significant in our previous analysis but are known to be overexpressed in ovarian tumors (Alam et al. 2008). Overexpression of
EPHB4 in particular has been implicated in numerous cancers; in
ovarian cancer, it is significantly associated with advanced disease
and correlates with poor outcome (Kumar et al. 2007). While these
findings have not been validated by orthogonal approaches, they
illustrate the potential for our method to generate new hypotheses
of events that may be driving carcinogenesis.
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By use of the CMDS algorithm, we identified 424 significant
focal RCNAs containing some 582 genes. Gene set analysis identified focal adhesion and ECM–receptor interaction as significantly
altered pathways. These findings are consistent with current
knowledge of ovarian carcinoma and other epithelial cancers, in
which dysregulation of cell–cell and cell–matrix signaling represents a key step in tumor development, growth, and invasion.
Taken together, these results suggest that our method for exomebased CNA detection both confirms and extends the results of
traditional approaches.
Importantly, the samples studied here all were processed using similar hybrid capture protocols (Agilent SureSelect) and were
sequenced on the same platform (Illumina GAIIx). By comparing
samples from the same individual sequenced under identical
conditions, our approach to CNA detection avoids GC content
and mapping biases that complicate traditional sequence-based
methods. However, the CNA calling could be confounded by
paired samples that were sequenced under different conditions or
on different sequencing platforms. Further, although we normalized for data input (unique bases mapped), it is possible that fluctuations in capture specificity and/or sequence representation
could influence sequence depth between sample pairs, which
might affect our results. One possible strategy to address this would
be to normalize for unique on target bases (i.e., capture specificity)
using the results of coverage reporting software such as RefCov
(T. Wylie and J. Walker, http://gmt.genome.wustl.edu/gmt-refcov/
current). Discordant read-pairs may also offer a source of supporting evidence for CNAs caused by structural variation (SV).
We are currently evaluating both strategies to improve sensitivity and specificity.
Exome sequencing has the potential to rapidly screen the
coding regions of tumor samples for somatic alterations. The
analysis methods described here will help realize that potential by
enabling the simultaneous identification of germline variants,
mutations, and SCNAs in matched tumor–normal pairs. By design,
an exome sequencing strategy prioritizes protein-altering mutations, which are not only easier to interpret in the context of
pathways and biological processes but may encode ‘‘druggable’’
targets. It is important to realize, however, that exome sequencing
surveys only ;1% of the tumor genome. This strategy will miss
many noncoding mutations, as well as larger events (e.g., SV) that
may contribute to tumor development and progression. Ultimately, WGS will be required to identify the full spectrum of somatic alterations in tumor genomes.

Methods
Mutation detection algorithm
Given pileup input for a tumor sample and matched normal
control, the mutation detection algorithm performs several steps
at each position. First, it determines if both samples meet the
minimum coverage requirement (by default, three reads with base
quality $20) and determines a genotype for each sample individually based upon the read bases observed. By default, a variant
allele must be supported by at least two independent reads and at
least 8% of all reads. If no variant allele meets the criteria, the
position is called wild type (homozygous reference) in that sample.
If multiple variant alleles are observed, the most-supported (by
read count, and then by base quality) variant allele is chosen.
Variants are called homozygous if supported by 75% or more of
all reads at a position; otherwise they are called heterozygous.
Positions where neither sample is determined to be variant are
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excluded unless the –validation flag is set to 1. Next, at positions
where one or both samples have a variant, the algorithm performs
a direct comparison between normal and tumor as follows.
If the genotypes do not match, then their read counts are
evaluated by one-tailed Fisher’s exact test in a two-by-two table (see
Supplemental Fig. 6), comparing the number of reference-supporting reads (outcome 1) and variant-supporting reads (outcome
2) observed in tumor (category 1) to the numbers that were observed in normal (category 2). If the resulting P-value meets the
significance threshold (default 0.10), then the variant is called
somatic (if the normal matches the reference) or LOH (if the normal is heterozygous). If the difference does not meet the significance threshold, the variant is called germline and processed as
described below.
If the genotypes match, the variant is called germline. The
variant P-value is computed by one-tailed Fisher’s exact test (FET)
in a two-by-two table, comparing the total number of referencesupporting reads and the total number of variant supporting reads
(normal and tumor values are combined) to the expected distribution for a nonvariant position due to sequencing error (0.01%).
For example, the expected read distribution for a nonvariant position with 5003 coverage in each sample would be 999 referencesupporting reads, and one variant-supporting read due to sequencing error.
Germline, LOH, and somatic mutations are further categorized as HC or LC by the VarScan processSomatic command. By
default, somatic mutations are deemed HC if the variant allele
frequency is at least 10% in tumor, <5% in normal, and the FET
P-value is less than 0.07. Germline variants are deemed HC if they
have at least 10% variant allele frequency in both normal and tumor samples. LOH variants are deemed HC if the variant allele
frequency is at least 10% in the normal sample and the FET P-value
is less than 0.07. Any variant not meeting the HC criteria is deemed
LC. Positions that are homozygous in normal but heterozygous in
tumor (gain of heterozygosity) or where the variant allele is not the
same (e.g., a SNP and an indel) are presumed to be sequencing/
alignment artifacts and are discarded.

CNA detection algorithm
Given pileup input for a tumor sample and matched normal, the
CNA detection algorithm first determines that at least one of the
samples meets the minimum coverage requirement. To reduce
noise from spurious differences at low coverage, the default setting
for this parameter (20) is higher than that of mutation detection.
Next, the algorithm computes the depth of high-quality bases
(phred base quality $20) individually for tumor and normal samples. These depths are recorded for each consecutive position until
(1) a gap in minimum coverage is encountered, (2) the end of the
chromosome is reached, or (3) the ratio of tumor depth to normal
depth changes significantly, as computed by Fisher’s exact test. For
each contiguous region, the relative copy number change (C) in
the tumor is inferred as the log base 2 of the normalized depth
ratio:
C = log 2 ððDT =DN Þ  ðI N =I T ÞÞ:
Here DT is the average tumor depth, DN is the average normal
depth, IN is the number of uniquely mapped bases in the normal
BAM, and IT is the number of uniquely mapped bases in the tumor
BAM. The number of uniquely mapped bases is computed using
SAMtools flagstat information for each BAM file, specifically as
I = RM  ð1  DupÞ  L;
where RM is the number of reads mapped, Dup is the proportion of
mapped reads marked as duplicates, and L is the average read
length. Raw copy number regions with chromosome, start posi-

tion, stop position, and log2 value underwent CBS in the DNAcopy
package (Seshan and Olshen 2010) to produce segmented calls
delineated by significant change-points of at least three standard
deviations (Supplemental Methods). Adjacent segments of similar
copy number from the CBS algorithm were merged by an internally developed Perl script (MergeSegments), and classified by
size. Events encompassing >25% of a chromosome arm were
classified as large-scale; all others were considered focal events.

Software implementation
The VarScan 2 core software was developed in Java; the false-positive filter was implemented in Perl. Binary executables, scripts,
and source code are free for noncommercial use and available at
http://varscan.sourceforge.net. The false-positive filter requires the
bam-readcount utility (D. Larson et al., https://github.com/genome/
bam-readcount), which is written and compiled in C.

Ovarian cancer data
The ovarian cancer data set, including exome sequence data, SNP
array data, and validated somatic mutations, was generated and
published by the Cancer Genome Atlas Research Network (Cancer
Genome Atlas Research Network 2011). The WGS data for the five
cases utilized in the cross-platform copy number comparison will
be described in a separate publication. Exome and WGS sequence
data are available in BAM format at the dbGaP database (http://
www.ncbi.nlm.nih.gov/gap). Identifiers for samples in this study
are in Supplemental Table 1.
Mutations were called in exome data for 151 tumor–normal
pairs by the VarScan somatic command with the following parameters: –min-coverage 4,–min-var-freq 0.08,–p-value 0.05,–strandfilter 1–min-avg-qual 20. HC mutations were filtered to remove false
positives using the criteria described in Table 1 (see Supplemental
Methods). Filter-passed somatic mutations were annotated using
gene structure and UCSC (Karolchik et al. 2003) annotation information, assigning each mutation to one of four tiers as previously described (Ley et al. 2008; Mardis et al. 2009). Only tier 1
mutations, which alter coding sequence (nonsynonymous, synonymous, splice site, or noncoding RNA), were reported in Figure 1
or selected for orthogonal validation. CNAs were called in exome
data for 142 tumor–normal pairs (nine poor-coverage tumors were
excluded) by the VarScan copynumber command with the following parameters: –min-coverage 20–min-region-size 100. Raw CNA
calls underwent CBS and a subsequent merging procedure as described in Supplemental Methods.

RCNA identification, annotation, and pathway analysis
The CMDS algorithm (Zhang et al. 2010) was applied to identify
regions of statistically significant RCNAs. For each tumor sample,
the merged segmented copy number events (see Supplemental
Methods) were cross-referenced with the coordinates of about
200,000 protein-coding exons to obtain the mean log2 of copy
number change for the start position and stop position of each
exon. CMDS was configured to run with a minimum of 20 markers
(exon starts or stops), corresponding to roughly one region tested
per gene. Regions meeting the significance threshold (P < 0.0001)
were merged if within 100 kb of one another, yielding a set of 520
candidate RCNA regions. These were visually reviewed to identify
target genes, and remove peaks encompassing six or more unrelated genes, as the target of these nonfocal events was unclear.
The cytoBand.txt and refGene.txt files from the UCSC Genome
Browser Database (Karolchik et al. 2003) version hg18 were used to
annotate CNA events with cytogenetic band and RefSeq gene in-
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formation, respectively, using a customized Perl script. Information on specific genes from the RefSeq and KEGG databases was
retrieved using GeneCards (Safran et al. 2002) version 3.0. Pathway-based analysis of 582 RCNA genes was performed using KEGG
and GO database information using WebGestalt Gene Set Analysis
Toolkit version 2.0 (http://bioinfo.vanderbilt.edu/webgestalt/) with
the default settings (hypergeometric test, BH correction, at least two
genes per category).
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